2512192-54-8
2512192-54-8
Chemical Structure
Eslicarbazepine Acetate-d3
- CAS No.: 2512192-54-8
- Formula:C17H13D3N2O3
- Molecular Weight:299.34
IUPAC Name: (S)-5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl-10,11,11-d3 acetate
InChIKey: QIALRBLEEWJACW-UGXZEXCXSA-N
SMILES: NC(N(C1=C(C=CC=C1)[C@@](OC(C)=O)(C2([2H])[2H])[2H])C3=C2C=CC=C3)=O
Biological Activity: Eslicarbazepine Acetate-d3 is the deuterium labeled Eslicarbazepine acetate (HY-B0703). Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Eslicarbazepine Acetate-d3 | Eslicarbazepine Acetate-d3 is the deuterium labeled Eslicarbazepine acetate (HY-B0703). Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Eslicarbazepine acetate (Standard) | ≥98% | Eslicarbazepine acetate (Standard) is the analytical standard of Eslicarbazepine acetate. This product is intended for research and analytical applications. Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Eslicarbazepine acetate-d4 | Eslicarbazepine acetate-d4 is deuterated labeled Eslicarbazepine acetate (HY-B0703). Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Eslicarbazepine acetate | 99.92% | Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
